|
|
| | 5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine Basic information |
| | 5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine Chemical Properties |
| Boiling point | 709.2±70.0 °C(Predicted) | | density | 1.168±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 9.32±0.40(Predicted) |
| | 5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine Usage And Synthesis |
| Uses | TH-Z816 is a reversible inhibitor againstKRAS(G12D)mutation with an IC50 value of 14 μM, which can be used in cancer research[1]. | | References | [1] Zhongwei Mao, et al. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discov. 2022 Jan 25;8(1):5. DOI:10.1038/s41421-021-00368-w |
| | 5,6,7,8-Tetrahydro-7-(8-methyl-1-naphthalenyl)-4-[(2R)-2-methyl-1-piperazinyl]-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidine Preparation Products And Raw materials |
|